Science Blog

The US and international effort to address the novel Coronavirus (COVID-19) pandemic is unprecedented. Experts from healthcare, public health, and policy are joining forces with experts in manufacturing and technology for the rapid deployment of innovative, lifesaving solutions. VivoSense, an expert in remote monitoring of physiological signals, is contributing to this effort through their advanced data analytics and Human Augmented AI platform.

Image Source: RSRT, Randol Family

VivoSense announces a series of new collaborations with the Rett Syndrome Research Trust (RSRT) to develop digital biomarkers that better assess the symptoms of Rett syndrome, focusing on autonomic dysfunction and other difficult-to-evaluate symptoms. The goal in developing these digital biomarkers is to better quantify and understand symptom impact on everyday life and to assess new treatments accurately.

The pace, pressures, work-life balance, and emotional aspects of a physician’s job put them at risk for burnout. A study by the American Medical Association and Mayo Clinic found that burnout rates were particularly increased for specialty practitioners. Drs. Nicholas Slamon and Rob Parker, pediatric ICU physicians at Nemours/Alfred I. duPont Hospital for Children in Wilmington, DE, used VivoSense^® and real-time biometrics of physician stress to study its effects on the care of pediatric patients.

Scientists are increasingly relying on wearable sensors and machine learning to develop digital biomarkers. However, their successful development requires the identification of physiological events relevant to the disease state. Here's an overview of the method we use to accurately and efficiently label physiological events from biosignals collected from wearable sensors.

As the leading provider of visualization and analysis software for data from wearable sensors, we are committed to continually improving VivoSense and expanding its capabilities for our academic research partners. Here are some of the highlights of our recent release of VivoSense^® 3.4.

ActiGraph, the leading provider of medical-grade wearable activity and sleep monitoring solutions, has announced a new partnership with data analytics specialist VivoSense. The partnership will enhance the ability of both companies to deliver sponsor access to secure, regulated, analyzed, and contextualized sensor data from patients participating in pharmaceutical clinical trials. VivoSense is a regulatory compliant, cloud based platform for the analysis of wearable sensor data. VivoSense with VivoCapture provides pharmaceutical sponsors with secure access to contextualized sensor data, metadata, analyzed, and raw signals. The platform makes use of Azure authentication and authorization, computing, and storage in a regulated sensor data warehouse.

Vivonoetics, a Microsoft Cloud Partner, now offers VivoSense in both the Azure Marketplace and AppSource. VivoSense is a regulatory compliant, cloud based platform for the analysis of wearable sensor data. VivoSense with VivoCapture provides pharmaceutical sponsors with secure access to contextualized sensor data, metadata, analyzed and raw signals. The platform makes use of Azure authentication and authorization, computing, and storage in a regulated sensor data warehouse.

San Diego, CA, March 5, 2019 — Biometric sensor provider Indie Health announces its partnership with data analytics specialist VivoSense, to accelerate the delivery of actionable insights and accurate monitoring of patients’ health status. Combining VivoSense software with Indie Health sensor data ensures complete data integrity and structures it within a secure, regulatory-compliant and auditable environment.

June 12, 2018 Newport Coast CA – VivoSense (Vivonoetics), the leading provider of visualization and analysis software for data from wearable sensors is excited to announce the release of VivoSense^® 3.2.

April 20, 2017 Newport Coast CA – Vivonoetics is proud to introduce VivoSense® 3.1 with features that will help you manage data and perform analysis even better.